. Lv-sacks, Y. I. Shamsuddin, . Yasinskaya, . Bouri, . Lanthier et al., Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, JAMA, vol.311, issue.4, pp.378-384, 2000.

, ICH E4 Dose response information to support drug registration. ICH Harmonised Tripartite Guideline, EMA, 1994.

. Dh-li, W. Whitmore, Y. Guo, and . Ji, Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials, Clinical Cancer Research, vol.23, issue.1, pp.13-20, 2017.

F. Bretz, J. Branson, and . Pinheiro, Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies, Biometrics, vol.61, issue.3, pp.738-748, 2005.

, Qualification Opinion of MCP-Mod as an efficient statistical methodology for model-based design and analysis of Phase II dose finding studies under model uncertainty. Committee for Medicinal Products for Human Use (CHMP), EMA, 2014.

J. Aouni, G. Bacro, . Toulemonde, . Colin, B. Darchy et al., Assessing Dunnett and MCP-Mod based approaches in two-stage dose-finding trials, Biostatistics and Health Sciences, 2019.

F. Miller, H. Guilbaud, and . Dette, Optimal Designs for Estimating the Interesting Part of a Dose-Effect Curve, Journal of Biopharmaceutical Statistics, vol.17, issue.6, pp.1097-1115, 2007.

. Lj-savage, The Foundations of Statistics, INC, 1954.

B. Bornkamp, F. Pinheiro, and . Bretz, MCPMod: An R Package for the Design and Analysis of Dose-Finding Studies, Journal of Statistical Software, vol.29, issue.7, pp.1-23, 2009.

J. Temple, Adaptive designs for Dose-finding trials, pp.1-206, 2012.

Z. Antonijevic, P. Pinheiro, . Fardipour, and . Lewis, Impact of Dose Selection Strategies Used in Phase II on the Probability of Success in Phase III, Statistics in Biopharmaceutical Research, vol.2, issue.4, pp.469-486, 2010.

. Lk-foo, Designs to balance cost and success rate for an early phase clinical study, Journal of Biopharmaceutical Statistics, vol.27, issue.1, pp.148-158, 2017.

M. Kirchner, H. Kieser, A. Götte, and . Schüler, Utility-based optimization of phase II/III programs, Statistics in Medicine, vol.35, issue.2, pp.305-316, 2016.

. Bj-gajewski, . Berry, M. Quintana, M. Pasnoor, . Dimachkie et al., Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot, Statistics in medicine, vol.34, issue.7, pp.1134-1149, 2015.

N. Thomas, V. Sweeney, and . Somayaji, Meta-Analysis of Clinical Dose-Response in a Large Drug Development Portfolio, Statistics in Biopharmaceutical Research, vol.6, pp.302-317, 2014.

E. Comets, Etude de la réponse aux médicaments par la modélisation des relations dose-concentration-effet, pp.1-84, 2010.

J. Aouni, G. Bacro, . Toulemonde, L. Colin, and . Darchy, On the use of utility functions for optimizing phase II/phase III seamless trial designs. Therapeutic Innovation & Regulatory Science, Under review, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02491531

. Dv-ravenzwaaij, S. D. Cassey, and . Brown, A simple introduction to markov chain monte-carlo sampling, Psychonomic Bulletin and Review, vol.25, issue.1, pp.143-154, 2018.

. Cj-geyer, . Robert, Y. Casella, . Fan, . Sisson et al., Handbook of markov chain monte carlo, pp.3-592, 2011.

J. Aouni, G. Bacro, B. Toulemonde, and . Sebastien, Utility-based dose-finding in practice: some empirical contributions and recommendations, Annals of Biostatistics & Biometric Applications, 2019.

C. Seila, Implementing the batch means method in simulation experiments, Proceedings of the 28th Conference on Winter Simulation, pp.214-221, 1996.

. Gs-fishman and . Yarberry, An implementation of the batch means method, INFORMS Journal on Computing, vol.9, issue.3, pp.231-318, 1997.

. Bw-schmeiser and . Song, Batching methods in simulation output analysis: What we know and what we don't, Proceedings of the 28th Conference on Winter Simulation, pp.122-127, 1996.

X. Paoletti, C. Ezzalfani, and . Tourneau, Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials, Annals of Oncology, vol.26, pp.1808-1812, 2015.

. Ap-verhagen, . Hc-de-vet, A. G. De-bie, M. Kessels, . Boers et al., The Delphi List: A Criteria List for Quality Assessment of Randomized Clinical Trials for Conducting Systematic Reviews Developed by Delphi Consensus, Journal of clinical epidemiology, vol.51, issue.12, pp.1235-1241, 1998.

. V-dragalin, . Bornkamp, . Bretz, . Miller, . Sk-padmanabhan et al., A simulation study to compare new adaptive dose-ranging designs, Statistics in Biopharmaceutical Research, vol.2, pp.487-512, 2010.